The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
Open accessAbstract
The major obstacle in cancer treatment is the resistance of cancer cells to therapies. Nrf2 is a transcription factor that regulates a cellular defense response and is ubiquitously expressed at low basal levels in normal tissues due to Keap1-dependent ubiquitination and proteasomal degradation. Recently, Nrf2 has emerged as an important contributor to chemoresistance. High constitutive expression of Nrf2 was found in many types of cancers, creating an environment conducive for cancer cell survival. Here, we report the identification of brusatol as a unique inhibitor of the Nrf2 pathway that sensitizes a broad spectrum of cancer cells and A549 xenografts to cisplatin and other chemotherapeutic drugs. Mechanistically, brusatol selectively reduces the protein level of Nrf2 through enhanced ubiquitination and degradation of Nrf2. Consequently, expression of Nrf2-downstream genes is reduced and the Nrf2-dependent protective response is suppressed. In A549 xenografts, brusatol and cisplatin cotreatment induced apoptosis, reduced cell proliferation, and inhibited tumor growth more substantially when compared with cisplatin treatment alone. Additionally, A549-K xenografts, in which Nrf2 is expressed at very low levels due to ectopic expression of Keap1, do not respond to brusatol treatment, demonstrating that brusatol-mediated sensitization to cisplatin is Nrf2 dependent. Moreover, a decrease in drug detoxification and impairment in drug removal may be the primary mechanisms by which brusatol enhances the efficacy of chemotherapeutic drugs. Taken together, these results clearly demonstrate the effectiveness of using brusatol to combat chemoresistance and suggest that brusatol can be developed into an adjuvant chemotherapeutic drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“brusatol has been shown to enhance the efficacy of chemotherapy by inhibiting Nrf2 [229,230].”
From Nrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease (2022) · cites this paper as [229]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE Pathway
Kensler, T. W., Wakabayashi, N., & Biswal, S. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141046 · Cited by 3,630
Kobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224
Dinkova-Kostova, A. T., Holtzclaw, W. D., Cole, R. N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., & Talalay, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398899 · Cited by 1,947
Keap1 Is a Redox-Regulated Substrate Adaptor Protein for a Cul3-Dependent Ubiquitin Ligase Complex
Zhang, D. D., Lo, S., Cross, J. V., Templeton, D. J., & Hannink, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10941-10953.2004 · Cited by 1,284
Self-citationMechanistic Studies of the Nrf2-Keap1 Signaling Pathway
Zhang, D. D. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600971974 · Cited by 1,105
Self-citationRamos-Gomez, M., Kwak, M.-K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., & Kensler, T. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051618798 · Cited by 1,102
Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060
Cullinan, S. B., Gordan, J. D., Jin, J., Harper, J. W., & Diehl, J. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8477-8486.2004 · Cited by 986
NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer
Hayes, J. D., & McMahon, M. J. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.12.008 · Cited by 870
Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2
Wang, X.-J., Sun, Z., Villeneuve, N. F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G. T., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn095 · Cited by 839
Self-citation
Cited by
Sorted by citations
Items 501–600 of 681
Martinez, R., Huang, W., Samadani, R., Mackowiak, B., Centola, G. A., Chen, L., Conlon, I. L., Hom, K., Kane, M. A., Fletcher, S., et al. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000266 · Cited by 9
Protein Phosphorylation and Redox Status: An as Yet Elusive Dyad in Chronic Lymphocytic Leukemia
Pagano, M. A., Frezzato, F., Visentin, A., Trentin, L., & Brunati, A. M. (2022) · Cancers · doi:10.3390/cancers14194881 · Cited by 9
Targeting ROS for Cancer Therapy
Dong, J., & Liu, B. (2016) · Chemotherapy Open access · doi:10.4172/2167-7700.1000199 · Cited by 9
Wang, J., Xu, J., Yang, S., He, L., Xu, W., Liu, Y., Cao, B., & Yu, S. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23685 · Cited by 8
Revisiting Neuroblastoma: Nrf2, NF-κB and Phox2B as a Promising Network in Neuroblastoma
Peggion, S., Najem, S., Kolman, J. P., Reinshagen, K., & Raluy, L. P. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040200 · Cited by 8
MEF2A, a gene associated with mitochondrial biogenesis, promotes drug resistance in gastric cancer
Shen, Y., Zhang, T., Jia, X., Xi, F., Jing, W., Wang, Y., Huang, M., Na, R., Xu, L., Ji, W., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167497 · Cited by 8
NRF2 activation in cancer and overview of NRF2 small molecule inhibitors
Ngo, H. H., Yu, B.-Y., Lee, J., Kim, H. W., & Keum, Y. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01557-x · Cited by 9
Wang, S., Lin, D., Cao, J., & Wang, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813682 · Cited by 8
Insights into the role of NRF2 in cancer provided by cancer genomics
Pölönen, P., & Levonen, A. (2016) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2016.09.002 · Cited by 9
Friend or Foe: Xenobiotic Activation of Nrf2 in Disease Control and Cardioprotection
Hedrich, W. D., & Wang, H. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-02997-y · Cited by 9
Brusatol Inhibits Proliferation, Migration, and Invasion of Nonsmall Cell Lung Cancer PC-9 Cells
Yang, L.-M., Zhou, W., Guo, Q., Fan, X., Huang, D.-Y., Sun, X., Yuan, J., Yu, H., Chen, H., & Zhang, J. (2022) · World Journal of Traditional Chinese Medicine · doi:10.4103/2311-8571.353662 · Cited by 7
ROS, Redox Regulation, and Anticancer Therapy
Bansal, M. P. (2023) · Springer eBooks · doi:10.1007/978-981-99-7342-2_9 · Cited by 7
Yang, H., Chan, O.-K., Huang, X., Liang, Y., Sun, N., Li, Y., Shi, Z., Zha, Q., Ouyang, D., Li, J., et al. (2025) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2025112 · Cited by 8
Tipping the balance: NRF2’s dual role in ferroptotic fate
de Souza, I., Teixeira, A. B. D. S., dos Santos, A. F., Angeli, J. P. F., & Rocha, C. R. R. (2026) · Oncogenesis · doi:10.1038/s41389-026-00630-4 · Cited by 9
Lim, J. S., Lee, S. H., Yun, H., Lee, D. Y., Cho, N., Yoo, G., Choi, J. U., Lee, K. Y., Bách, T. T., Park, S.-J., et al. (2023) · Antioxidants · doi:10.3390/antiox12101792 · Cited by 7
Verdina, A., Segni, M. D., Amoreo, C. A., Sperduti, I., Buglioni, S., Mottolese, M., Rocco, G. D., & Soddu, S. (2020) · Oncology Reports · doi:10.3892/or.2020.7912 · Cited by 7
The Anticancer Potential of Quassinoids—A Mini-Review
Lu, C., Lu, S., Di, D., Tao, W., Fan, L., Duan, J., Zhao, M., & Che, C. (2024) · Engineering · doi:10.1016/j.eng.2023.11.022 · Cited by 6
Ko, J. M. Y., Guo, C., Leung, A. K.-K., Chan, S. C.-Y., Lo, A. W. I., Tao, L., Ng, H. Y., Wong, C. W.-Y., Law, S. Y.-K., Wong, Y., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03113-2 · Cited by 6
Zhang, S.-H., Zhang, H., Jia, Y.-Z., Wang, Z., You, Z.-H., Lian, C.-Y., & Wang, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113180 · Cited by 6
KEAP1-NRF2 Pathway as a Novel Therapeutic Target for EGFR-Mutant Non-small Cell Lung Cancer
Choi, J.-S., Kang, H.-M., Na, K., Kim, J., Kim, T., Jung, J., Lim, H., Seo, H., & Lee, S. H. (2024) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2024.0087 · Cited by 6
He, F., Gai, J., Wang, J., Tang, L., Liu, Y., & Feng, Q. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12394 · Cited by 6
Mendez, B., Reyes, J., Conde, I., Ramos, Z., Lozada-Delgado, E. L., Cruz, A. M., Asencio, G., Carvajal, A., Dharmawardhane, S., Piñero, D. M., et al. (2020) · Plants · doi:10.3390/plants9010093 · Cited by 6
Zhang, Y., Yang, D., Qin, H., He, L., Huang, J., Tang, D., Xu, Z., Chen, Z., & Li, Y. (2021) · Oncology Reports · doi:10.3892/or.2021.7932 · Cited by 6
Tamari, S., Menju, T., Toyazaki, T., Miyamoto, H., Chiba, N., Noguchi, M., Ishikawa, H., Miyata, R., Kayawake, H., Tanaka, S., et al. (2022) · Oncology Reports · doi:10.3892/or.2022.8386 · Cited by 6
Holmes, N. P., & Dakwar, A. R. (2015) · Vision Research · doi:10.1016/j.visres.2015.08.019 · Cited by 6
Liu, F., Li, S., Huang, C., Bi, Z., Xiang, X., Zhang, S., Yang, R., & Lu, Z. (2025) · RSC Advances · doi:10.1039/d5ra00108k · Cited by 5
The role of NRF2 in human cancers: Pre-clinical insights paving the way for clinical trials
Pei, Y., Yin, J., Liu, J., Liu, D., Wu, Q., Cai, X., Han, M., Tian, Y., Yang, L., & Liu, S. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101358 · Cited by 5
Zhao, J., Jiang, H., Zhao, K., Liu, T., Zhang, Q., Zhao, Z., Wang, J., You, Q., Lu, M., & Jiang, Z. (2025) · Chemical Science · doi:10.1039/d5sc04324g · Cited by 5
Xu, W., Yang, H., Zhou, Y., Guo, R., Liu, J., Wei, F., & Lin, Y. (2025) · Nutrients · doi:10.3390/nu17203285 · Cited by 5
Verdina, A., & D’Orazi, G. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl39800 · Cited by 6
Zhu, Y. Q., Liu, M., Fan, X., Xu, Y., Diao, X., Bi, J., Wan, X., Assaraf, Y. G., Kwok, H. F., & Chen, L. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010841 · Cited by 5
Nguyen, M. H., Nguyen, T. Y. N., Chen, Y., Le, H., Vo, H. T., & Yen, C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38411 · Cited by 5
Lu, H., Li, Y., Zhang, Y., Qin, W., Su, Z., Qiu, S., & Zheng, L. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl37810 · Cited by 5
Pyrimethamine and a potent analog inhibit NRF2 by suppressing one-carbon metabolism
Chembo, J., Bowman, B. M., LaPak, K. M., Wilkerson, E., Wamsley, N. T., Paiboonrungruang, C., Cho, K., Medcalf, M. R., Wang, H., Patti, G. J., et al. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110659 · Cited by 5
Xiang, Y., Dai, S., Ding, L., Zhu, X., Su, J., Chen, B., & Wu, M. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.105024 · Cited by 5
[Progress of NRF2 Signaling Pathway in Promoting Proliferation of Non-small Cell Lung Cancer].
Fang, Y., Zou, X., Hu, S., & Ji, L. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.102.37 · Cited by 5
Metabolic drivers of genome instability in cancer: mechanisms and therapeutic opportunities
Wang, Y.-S., Qian, L.-H., Liu, C., & Yu, K. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00775-3 · Cited by 4
Redox control of NRF2 signaling in oocytes harnessing Porphyra derivatives as a toggle
Kim, E., Cha, D., Jang, S. J., Cho, J., Moh, S. H., & Lee, S. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.12.033 · Cited by 4
Lin, G., Zheng, R.-Q., Xu, Z., Xing, S., Wu, H.-F., Xie, Y., Huang, H., & Liu, Y. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156468 · Cited by 4
Meng, X., Xu, T., Xu, L., Du, Y., Huo, F., Jin, A., Li, Y., Yan, C., Zhang, Y., & Huang, T. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117912 · Cited by 4
Lu, H. J., Fu, W., Xia, Y., Yan, Y., Shu, C.-H., Chen, Y., Xu, C., Zheng, P., Shen, X., Cui, R., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02657-9 · Cited by 4
Brusatol suppresses malignant progression of glioma via modulating the miR-574–5p/USP10/PLK1 axis
Ma, B., Wang, L., Li, J., Zhang, B., Wang, Y., Li, N., Shen, D., & Han, C. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157142 · Cited by 4
Zhang, K., Ni, X., Wang, C., Guo, J., Fan, W., Jiang, T., & Zhang, G. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157585 · Cited by 4
Self-citationInsight into Nrf2: a bibliometric and visual analysis from 2000 to 2022
Ma, Y., Wang, Z., & Hu, Y. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1266680 · Cited by 4
Miao, J., Chen, S., Cao, H., Ding, Z., Li, Y., Wang, W., Nundlall, K., Deng, Y., & Li, J. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23714 · Cited by 4
Zhang, J., Wu, Y., Xu, H., Zhang, Y., Ren, P.-Y., Xian, Y., & Lin, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116977 · Cited by 4
Zhang, J., Xu, H., Wu, Y., Cho, W. C. S., Li, Y., Ren, P., Xian, Y., & Lin, Z. (2024) · Acta Materia Medica · doi:10.15212/amm-2024-0016 · Cited by 4
Conditioned Media Downregulates Nuclear Expression of Nrf2
Sarkar, S., Payne, C. K., & Kemp, M. L. (2013) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-013-0272-0 · Cited by 4
Huang, C., Wang, F., & Chan, W. (2022) · Toxicology Research · doi:10.1093/toxres/tfac057 · Cited by 4
Understanding the Role of NRF2 Signalling in Cancer
Basalingappa, K. M., Singh, P. G., Gopenath, T. S., Ramesh Bharadwaj, M. N., & Ilangovan, R. (2022) · Current Protein and Peptide Science · doi:10.2174/1389203723666220914120325 · Cited by 4
Suwattanasophon, C., Reiner, A. T., Alberdi-Cedeño, J., Pignitter, M., Somoza, V., König, J. S., Lamtha, T., Wanaragthai, P., Kiriwan, D., & Choowongkomon, K. (2023) · ACS Omega · doi:10.1021/acsomega.3c02931 · Cited by 4
Garufi, A., Pettinari, R., Monteonofrio, L., Puliani, G., Virdia, I., Appetecchia, M., Marchetti, F., Cirone, M., Soddu, S., & D’Orazi, G. (2024) · Oncology Reports · doi:10.3892/or.2024.8695 · Cited by 4
Liang, X., & Wang, R. (2021) · Visual Neuroscience · doi:10.1017/s095252382100002x · Cited by 4
Wondrak, G. T. (2014) · Springer eBooks · doi:10.1007/978-94-017-9421-3_13 · Cited by 4
Chembo, J., Bowman, B. M., LaPak, K. M., Wilkerson, E., Paiboonrungruang, C., Cho, K., Medcalf, M. R., Patti, G. J., Dolle, R. E., Chen, X. L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.13.637433 · Cited by 4
de Klerk, D. J., de Keijzer, M. J., Franchi, L. P., Tian, J., Gureev, M., Ge, Y., Mesquita, B. S., Saelman, G., herteryck, I. V., Dias, L. M., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117620 · Cited by 3
Lu, M., Yang, Z., Xin, Y., Zhang, Y., Jiang, S., Zhu, J., You, Q., Zhao, Z., & Jiang, Z. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.05.030 · Cited by 3
Chen, J., Dan, L., Jie, Y. A. N. G., Cai, X., Wei, G., & Cao, P. (2022) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0389 · Cited by 3
Quassinoids as Promising Anti-cancer Agents
Mishra, T., Saima, & Banik, B. K. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673313760240911160930 · Cited by 3
Su, S., Wu, X., Zhu, Y., Yang, S., Lu, K., Zhang, X., Zhang, D., & Wang, X. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113542 · Cited by 3
Self-citationCYP4F11, an NRF2 Target Gene, Promotes Hepatocellular Carcinoma Cell Growth
Chen, J., Trindl, C. A., Ye, H., Huang, D., Ooi, A., Garcia, J. G. N., Chapman, E., & Zhang, D. D. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23925 · Cited by 3
Self-citationNrf2 – Two Faces of Antioxidant System Regulation
Pastorek, M., Müller, P., & Vojtěšek, B. (2015) · Klinicka onkologie · doi:10.14735/amko20152s26 · Cited by 3
Ştefanache, T., Forna, N. C., Bădescu, M., Jitaru, D., Dragos, L. M., Rezuș, C., Diaconescu, B., Bădulescu, O. V., Rezuş, E., Ciocoiu, M., et al. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8117 · Cited by 3
Liu, Z. (2020) · International Journal of Ophthalmology · doi:10.18240/ijo.2020.08.02 · Cited by 3
Targeting tumor glycolysis metabolism in oral squamous cell carcinoma cells by brusatol
Zhang, G., Wu, Y., Chen, S., Su, Y., Yin, P., Fu, J., & Zhang, X. (2022) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2022.100172 · Cited by 3
Chen, D., Chen, S., Zhou, F., Chen, L. B., & Chen, M. (2023) · ChemMedChem · doi:10.1002/cmdc.202300282 · Cited by 3
Laude, J. M., Picart, M. R. D., Lim, A. L., Tun, J. O., Ramones, C. M. V., Rellin, K. F., Chicote, M. O., Belen, E., Ratnayake, R., Matthews, J., et al. (2022) · SciEnggJ · doi:10.54645/fktg97181 · Cited by 3
Wu, Z., Zhang, H., Li, J., Diao, Y., Huang, M.-J., Gao, D.-Y., Liang, C., & Luo, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1337179 · Cited by 3
Reactive Oxygen Species: Friends or Foes of Lung Cancer?
Guha, D., Banerjee, S., Mukherjee, S., Dutta, A., & Das, T. (2019) · Springer eBooks · doi:10.1007/978-981-32-9366-3_14 · Cited by 4
Ji, Y., Zhu, X., Shi, Y., Fang, R., Sun, Y., Ruan, Y., Zhou, L., Ge, Y., Luo, Q., Zhang, J., et al. (2025) · Biomolecules · doi:10.3390/biom15060812 · Cited by 2
Peng, Y., Shi, X., Wang, Q., Pan, Y., Wang, X., Yan, K., Feng, Z., Zheng, J., & Wang, J. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118298 · Cited by 2
Liu, H., Wang, L., Hu, M., Hua, J., LIAN, X., Lian, C., & Zhang, J. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128383328250808123933 · Cited by 2
Jayakumar, D., Narasimhan, K. K. S., Rajkumar, A., Panchalingam, G. P., Chandrasekar, N., Ravikumar, V., & Kalaiselvi, P. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70198 · Cited by 3
Mechanistic role of Nrf2 modulators in lipid peroxidation: a perspective towards carcinogenesis
Singh, A., Kukreti, R., Saso, L., & Kukreti, S. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001372 · Cited by 2
Ijaz, S., Iqbal, J., Abbasi, B. A., Zarshan, F., Yaseen, T., Ullah, Z., Uddin, S., Kanwal, S., Mahmood, T., Setzer, W. N., et al. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70142 · Cited by 2
Yang, M., Zhang, Z., Su, X., Li, J., Liu, H., Wang, S. N., Yousuf, W., Zhang, Y., Guo, S., Dg, L., et al. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178556 · Cited by 2
Hikisz, P., Adamus-Grabicka, A. A., & Budzisz, E. (2026) · Molecules · doi:10.3390/molecules31030534 · Cited by 2
Michilli, A., Bassi, C., Moshiri, F., Siena, B. D., Marinaro, R., Callegari, E., Negrini, M., & Sabbioni, S. (2026) · BioTech · doi:10.3390/biotech15010018 · Cited by 2
Targeting NRF2 addiction in cancer: synthetic lethal strategies beyond direct inhibition
Gebru, M. T., & Stokoe, D. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1856014 · Cited by 2
Jebanesan, D. Z. P., Illangeswaran, R. S. S., Rajamani, B. M., Vidhyadharan, R. T., Das, S., Bijukumar, N. K., Balakrishnan, B., Mathews, V., Velayudhan, S. R., & Balasubramanian, P. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05742-8 · Cited by 2
Razumovskaya, A. V., Silkina, M. O., Nikulin, S. V., Tonevitsky, A., & Alekseev, B. Y. (2024) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-024-06093-0 · Cited by 2
Targeting the Keap1/Nrf2 axis in cancer: molecular mechanisms and pharmacological interventions
Xia, Y., Xu, Z., Yuan, X., & Chu, Q. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01578-9 · Cited by 2
Ueda, H., Takahashi, K., & Watanabe, K. (2013) · Vision Research · doi:10.1016/j.visres.2013.02.008 · Cited by 2
Nrf2 Contributes to the Poor Prognosis and Chemoresistance
Syu, J.-P., Chi, J., & Kung, H. (2016) · InTech eBooks · doi:10.5772/65105 · Cited by 2
Research Progress of Aldehyde Ketone Reductase for Asymmetric Catalysis of Chiral Compounds
Li, S., Zhu, Z., Wang, J., Guo, Q., Xu, P., Sun, D., Qin, H., & Lu, F. (2017) · Lecture notes in electrical engineering · doi:10.1007/978-981-10-4801-2_80 · Cited by 2
The Keap1-Nrf2 Signaling Pathway in Lung Cancer
Raghunath, A., Raju, N., & Sundarraj, K. (2021) · Springer eBooks · doi:10.1007/978-981-33-6827-9_30 · Cited by 2
Bhattacharjee, S. (2019) · Springer eBooks · doi:10.1007/978-981-32-9366-3_16 · Cited by 2
Survival Strategy and Disease Pathogenesis According to the Nrf2‐Small Maf Heterodimer
Morita, M., & Motohashi, H. (2011) · doi:10.1002/9781118148143.ch5 · Cited by 2
Experience of Ombudsman at Lev Hasharon Mental Health Center.
Sigal, M., Kodesh, A., & Preisman, O. (2000) · PubMed · Cited by 2
Tian, Z., Yang, Y. M., Wu, H., Chen, Y., Jia, H., Zhu, L., He, R., Jin, Y., Zhou, B., Ge, C., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1564524/v1 · Cited by 2
Wu, Y., Zhang, G., Yin, P., Wen, J., Su, Y., & Zhang, X. (2024) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2024.106043 · Cited by 1
Yu, X., Xiang, L., An, J., Li, S., Hu, C., Gui, Y., Wang, Y., Bao, X., & Wang, D. (2025) · Arabian Journal of Chemistry · doi:10.25259/ajc_23_2024 · Cited by 1
Ma, C., Song, J., Feng, H., Kui, X., Liu, S., Shi, S., Li, X., & Tang, L. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117328 · Cited by 1
Circadian rhythms, NRF2 signalling and redox homeostasis: A holy grail for a healthy life course?
Sutton, E., & Pekovic‐Vaughan, V. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.05.318 · Cited by 2
Zhao, Z., Lu, H., Zhang, J. Y., Zhao, J., Wang, J., Zhu, T., Xu, S., You, Q., Lu, M., & Jiang, Z. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00096 · Cited by 1
NRF2-mediated ferroptosis suppression defines a cancer-specific vulnerability in tumors
Huang, D., Zhang, M., Stansfield, B., Ahmed, M., Xu, T., Alexander, L., Anandhan, A., Ma, M., Liu, P., Yang‐Hartwich, Y., et al. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104352 · Cited by 1
Self-citationLi, J., Zheng, D., Zhen, B., Sun, Y., Chen, F., Zhan, K.-X., Wei, N., & Zhang, L. (2017) · Planta Medica · doi:10.1055/s-0043-117414 · Cited by 1
Identification of narciclasine as a novel NRF2 inhibitor
Ngo, H. H., Yu, B.-Y., Lee, J.-E., Kim, H. W., & Keum, Y. (2025) · Free Radical Research · doi:10.1080/10715762.2025.2451679 · Cited by 1
Sun, Z., Cao, Y., & Zhai, L. (2017) · Medicine · doi:10.1097/md.0000000000005930 · Cited by 1
Eraslan, E., Tanyeli̇, A., Güler, M. C., Akdemi̇r, F. N. E., Nacar, T., TOPDAĞI, Ö., & Polat, E. (2020) · Turkish Bulletin of Hygiene and Experimental Biology · doi:10.5505/turkhijyen.2020.75232 · Cited by 1
Metadata
- Authors
- Ren, D., Villeneuve, N. F., Jiang, T., Wu, T., Lau, A., Toppin, H. A., & Zhang, D. D.
- Affiliations
- Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ 85721;
- University of Arizona (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2011-01-04
- Volume
- 108
- Issue
- 4
- Pages
- 1433-1438
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3029730
- OpenAlex
- W2077950988
- Cited by
- 673
- References
- 47
- Citations by year
- 2026: 41 · 2025: 43 · 2024: 42 · 2023: 48 · 2022: 59 · 2021: 47 · 2020: 65 · 2019: 48 · 2018: 44 · 2017: 52 · 2016: 48 · 2015: 38 · 2014: 36 · 2013: 34 · 2012: 21
- FWCI
- 12.45
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (ES006694)
- National Institute of Environmental Health Sciences (ES-006694, R01ES015010, P30ES006694)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
- Keywords
- brusatol, Nrf2, chemoresistance, cisplatin, Keap1, ubiquitination, proteasomal degradation, apoptosis, A549 xenograft, drug detoxification, adjuvant chemotherapy, lung cancer
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Drug Synergism, Glutathione, HeLa Cells, Humans, Lung Neoplasms, Mice, Nude, Immunoblotting, Molecular Structure, Signal Transduction, Apoptosis, Xenograft Model Antitumor Assays, Quassins, Intracellular Space, Cell Line, Tumor, Cell Proliferation, NF-E2-Related Factor 2, Mice, Ubiquitination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
